Tesamorelin side effects most often involve the injection site, joints and fluid retention. In pooled 26-week trials, injection-site reactions occurred in 17% of participants receiving tesamorelin versus 6% receiving placebo; arthralgia occurred in 13% versus 11%. Peripheral edema, muscle pain and tingling were less common. The label also warns about glucose intolerance and elevated IGF-1. Active cancer is a contraindication because tesamorelin increases growth signaling, but clinical trials have not shown that tesamorelin causes cancer.
Tesamorelin side effects reported in trials
The clearest numbers come from two phase 3 studies pooled across 806 adults with HIV-associated abdominal fat accumulation. During the placebo-controlled phase, 543 received tesamorelin and 263 received placebo. The current U.S. label groups reactions that occurred more often with tesamorelin this way:
| Adverse reaction | Tesamorelin | Placebo |
|---|---|---|
| Injection-site reaction | 17% | 6% |
| Arthralgia (joint pain) | 13% | 11% |
| Myalgia (muscle pain) | 6% | 2% |
| Peripheral edema | 6% | 2% |
| Paresthesia (tingling or pins and needles) | 5% | 2% |
The injection-site category included redness, itching, rash, hives, pain, swelling, irritation and bleeding. These are group averages, not a prediction for one person. Trial rates also cannot establish what will happen with a different formulation.
The 2007 pivotal trial enrolled 412 participants, 86% of them men. Overall adverse-event frequency was not significantly different between groups, although more tesamorelin participants stopped because of an adverse event (Falutz et al., New England Journal of Medicine, 2007). The larger pooled analysis likewise described tesamorelin as generally well tolerated, but found treatment-related events in 53.2% of the tesamorelin group versus 36.5% of the placebo group and discontinuation for an event in 9.6% versus 6.1% (Falutz et al., Journal of Clinical Endocrinology & Metabolism, 2010).
Why swelling, joint pain and tingling can travel together
Tesamorelin prompts the pituitary to release growth hormone, which in turn raises IGF-1. That pathway can also cause fluid retention. Extra tissue fluid helps explain why edema, joint discomfort, tingling and carpal-tunnel-type symptoms appear together in the label.
That is the useful mechanism-level summary. What tesamorelin does owns the fuller explanation, while tesamorelin dosage decisions covers how a prescriber sets and reviews a regimen. Side effects should not be used to reverse-engineer a dose.
Glucose and IGF-1 need monitoring
The two lab issues are different. IGF-1 is expected to rise because it sits directly downstream of growth-hormone signaling. Glucose can rise because growth hormone can reduce insulin sensitivity in some people.
In the pooled label data, 5% of tesamorelin-treated participants reached an HbA1c of at least 6.5% by week 26, compared with 1% on placebo. The estimated hazard ratio was 3.3, with a wide 95% confidence interval of 1.4 to 9.6. That does not mean most people developed diabetes. It means the threshold was crossed more often in the treatment group, so baseline and periodic glucose checks matter.
The label also reports that after 26 weeks, 47% of treated participants had IGF-1 above 2 standard-deviation scores and 36% were above 3. It calls for IGF-1 monitoring and reconsideration when elevation remains substantial, especially without a clear response. A separate 12-month randomized study of 404 adults found no significant group-level worsening in glucose measures, illustrating why an average trial result does not replace individual lab follow-up (Falutz et al., Journal of Acquired Immune Deficiency Syndromes, 2010).
Does tesamorelin cause cancer?
Clinical trials have not shown that tesamorelin causes cancer. The caution exists for a different reason: tesamorelin increases endogenous growth hormone and IGF-1, and both are growth signals. The label therefore contraindicates treatment during an active malignancy. For a previously treated, stable cancer, it calls for an individual assessment of possible benefit against the possibility of reactivating the underlying disease.
This is a theoretical and biologically plausible concern, not proof of causation. Lifetime rodent carcinogenicity studies have not been conducted, and the pivotal human studies were not designed or long enough to rule out uncommon long-latency outcomes. A 2022 endocrine review recommends age-appropriate cancer screening and states that tesamorelin itself has not been shown to increase cancer risk (Fourman and Grinspoon, Journal of Clinical Endocrinology & Metabolism, 2022).
The right intake questions therefore include active cancer, prior cancer treatment and whether routine screening is current. A rising IGF-1 result is a monitoring signal for the prescriber; it is not a cancer diagnosis.
When a side effect changes the plan
Mild localized redness or itching and brief joint or muscle discomfort fit the known trial profile. A clinician should hear about swelling that persists, numbness or hand pain suggestive of carpal tunnel, meaningful changes in blood sugar, or symptoms that are getting worse instead of settling.
Hypersensitivity reactions occurred in 4% of label-trial participants and included itching, redness, flushing, hives and rash. Facial or throat swelling, widespread hives, or trouble breathing needs urgent medical care. New evidence of a recurrent malignancy also requires prompt clinical review under the label.
Pregnancy, active malignancy and disruption of the hypothalamic-pituitary axis are labeled contraindications. Diabetes, a prior stable malignancy and medicines affected by growth-hormone signaling require closer review rather than a one-size-fits-all answer. The prescriber decides whether a symptom calls for observation, lab testing, a change, or discontinuation; this article is not a substitute for that decision.
Brand and compounded tesamorelin are different products
Promise's tesamorelin is dispensed as a compounded medication, which is different from an FDA-approved product: the formulation offered here is not FDA-approved. The approved brand Egrifta is labeled for reducing excess abdominal fat in adults with HIV-associated lipodystrophy; that indication and its trial results do not automatically carry over to compounded use.
The practical standard is accountable care: a known formulation, a pharmacy label, baseline history and a clinician who reviews symptoms and labs. Tesamorelin versus sermorelin owns the comparison between those compounds rather than treating their safety profiles as interchangeable.
At Promise, a licensed provider reviews every request; not everyone qualifies, and whether a compounded formulation is appropriate is a decision between the patient and the prescriber.